SynapDx Autism Gene Expression Analysis Study (SAGA)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01716845 |
Recruitment Status :
Completed
First Posted : October 30, 2012
Last Update Posted : December 17, 2014
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
This study will prospectively enroll approximately 660 children, at least 18 months and less than 5 years of age, who have been referred to a pediatric developmental evaluation centers. Enrolled children will have blood drawn for RNA gene expression analysis and undergo a clinical evaluation to determine the presence or absence of a diagnosis of ASD.
The sequential co-primary objectives of this study are:
- To develop an algorithm to classify blood RNA gene expression patterns to maximize agreement between the classification and a clinical assessment of presence or absence of Autism Spectrum Disorders (ASD).
- To prospectively assess the clinical sensitivity and specificity of the blood RNA gene expression classification algorithm (the SDX-002 test) in children referred to a developmental evaluation clinic for a possible developmental disorder.
Condition or disease |
---|
Autism |
Study Type : | Observational |
Estimated Enrollment : | 660 participants |
Observational Model: | Cohort |
Time Perspective: | Prospective |
Official Title: | SynapDx Autism Spectrum Disorder Gene Expression Analysis Study |
Study Start Date : | October 2012 |
Actual Primary Completion Date : | December 2014 |
Actual Study Completion Date : | December 2014 |

Group/Cohort |
---|
Development group 1 |
Development group 2 |
Development group 3 |
Validation group |
- RNA gene expression in peripheral blood [ Time Frame: within 30 days of collection ]
Biospecimen Retention: Samples With DNA

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Months to 5 Years (Child) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Sampling Method: | Probability Sample |
Inclusion Criteria:
- Referred to a developmental evaluation centers for evaluation of a possible developmental disorder, other than isolated motor problems.
- Age >= 18 months and < 5 years.
- Parent/legal guardian has been informed about the study and has signed an informed consent form.
Exclusion Criteria:
- Prior reliable diagnosis of Autism Spectrum Disorder (i.e. prior evaluation by a multi-disciplinary team has already reliably established Autism Spectrum Disorder diagnosis).
- Unable or unwilling to complete study procedures

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01716845
United States, Massachusetts | |
Children's Hospital Boston | |
Boston, Massachusetts, United States, 02115 |
Responsible Party: | SynapDx |
ClinicalTrials.gov Identifier: | NCT01716845 |
Other Study ID Numbers: |
12001 |
First Posted: | October 30, 2012 Key Record Dates |
Last Update Posted: | December 17, 2014 |
Last Verified: | December 2014 |
autism autism spectrum disorders RNA gene expression developmental delay |
Autistic Disorder Autism Spectrum Disorder Child Development Disorders, Pervasive Neurodevelopmental Disorders Mental Disorders |